VincentAPettingillPPettingillR, et al. Association of leucine-rich glioma inactivated protein 1, contactin-associated protein 2, and contactin 2 antibodies with clinical features and patient-reported pain in acquired neuromyotonia. JAMA Neurol. 2018;75:1519-1527. doi:10.1001/jamaneurol.2018.2681
2.
IraniSRAlexanderSWatersP, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010;133:2734-2748. doi:10.1093/brain/awq213
3.
IraniSRBuckleyCVincentA, et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology2008;71:1647-1648. doi:10.1212/01.wnl.0000326572.93762.51
4.
SilbergeldEKSilvaIANylandJF. Mercury and autoimmunity: implications for occupational and environmental health. Toxicol Appl Pharmacol. 2005;207(2 suppl):282-292.
5.
HacohenYSinghRRossiM, et al. Clinical relevance of voltage-gated potassium channel–complex antibodies in children. Neurology. 2015;85:967-975.
6.
KleinCJLennonVAAstonPAMcKeonAPittockSJ. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology. 2012;79:1136-1144. doi:10.1212/WNL.0b013e3182698cab
7.
van SonderenAPetit-PedrolMDalmauJTitulaerMJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol. 2017;13:290-301. doi:10.1038/nrneurol.2017.43
8.
CaravatiEMErdmanARChristiansonG, et al. Elemental mercury exposure: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2008;46:1-21. doi:10.1080/15563650701664731
9.
BrannanEHSuSAlversonBK. Elemental mercury poisoning presenting as hypertension in a young child. Pediatr Emerg Care. 2012;28:812-814. doi:10.1097/PEC.0b013e3182628a05
